Phase II drugs that target cholinergic receptors for the treatment of overactive bladder

Bibliography

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;103:1132-9
   Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study. Eur Urol 2006;50:1306-15
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. BJOG 1997;104:1374-9
   Web of Science ®Google Scholar
• Giarenis I, Mastoroudes H, Srikrishna S, et al. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? BJU Int 2013;112:501-7
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202-9
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Int J Urol 2009;16:126-42
   PubMed Web of Science ®Google Scholar
• Marinkovic SP, Rovner ES, Moldwin RM, et al. The management of overactive bladder syndrome. BMJ 2012;344:38-44
   Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188:2455-63
   PubMed Web of Science ®Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55:33-46
   PubMed Web of Science ®Google Scholar
• Garely AD, Borrows LJ. Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 2002;3:827-33
   PubMedGoogle Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53
   PubMed Web of Science ®Google Scholar
• Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010;29:112-15
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011;59:377-86
   PubMed Web of Science ®Google Scholar
• D’Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14:291-301
   PubMed Web of Science ®Google Scholar
• Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009;65:309-14
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008;102:774-9
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90
   PubMed Web of Science ®Google Scholar
• Hedge SS, Choppin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997;120:1409-18
   PubMed Web of Science ®Google Scholar
• Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001;21:243-8
   PubMedGoogle Scholar
• Fetscher C, Fleichman M, Schmidt M, et al. M(3) muscarinic receptor mediate contraction of human urinary bladder. Br J Pharmacol 2002;136:641-3
   PubMed Web of Science ®Google Scholar
• Kories C, Czyborra C, Fetscher C, et al. Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3? Naunyn Schmiedeberg’s Arch Pharmacol 2003;367:524-31
   Google Scholar
• Schneider T, Fetscher C, Krege S, et al. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004;309:1148-53
   PubMed Web of Science ®Google Scholar
• Schneider T, Hein P, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2+ sources. J Pharmacol Exp Ther 2004;308:47-53
   PubMed Web of Science ®Google Scholar
• Harriss DR, Marsh KA, Birmingham AT, et al. Expression of muscarinic M3-receptor coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 1995;154:1241-5
   PubMed Web of Science ®Google Scholar
• Nandigama R, Ibañez-Tallon I, Lips KS, et al. Expression of nicotinic acetylcholine receptor subunit mRNA in mouse bladder afferent neurons. Neuroscience 2013;229:27-35
   PubMed Web of Science ®Google Scholar
• Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002;22:133-45
   PubMedGoogle Scholar
• Kumar V, Cross RL, Chess-Williams R, et al. Recent advances in basic science for overactive bladder. Curr Opin Urol 2005;15:222-6
   PubMed Web of Science ®Google Scholar
• Manshield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005;144:1089-99
   PubMed Web of Science ®Google Scholar
• Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 2007;80:2303-7
   PubMed Web of Science ®Google Scholar
• Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011;72:186-96
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002;366:97-103
   PubMed Web of Science ®Google Scholar
• Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. 32nd Annual Meeting of the International Continence Society; 28-30 August 2002; Heidelberg, Germany
   Google Scholar
• Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007;30:54-8
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008;101:1036-42
   PubMed Web of Science ®Google Scholar
• Wiedemann A, Schwantes PA. Antimuscarinic drugs for the treatment of overactive bladder: are they really the same? A comparative review of data pertaining to pharmacological and physiological aspects. Euro J Geriatr 2007;9(Suppl 1):29-42
   Google Scholar
• Glavind K, Chancellor M. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J 2011;22:907-17
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Toler SM, Yohannes D, Lippiello P. Anticholinergic therapy for overactive bladder: a nicotinic modality? Med Hypotheses 2013;81:456-8
   PubMed Web of Science ®Google Scholar
• Beckel JM, Kanai A, Lee SJ, et al. Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol Renal Physiol 2006;290:F103-10
   PubMed Web of Science ®Google Scholar
• Beckel JM, Birder LA. Differential expression and function of nicotinic acetylcholine receptors in the urinary bladder epithelium of the rat. J Physiol 2012;590:1465-80
   PubMed Web of Science ®Google Scholar
• Kim J, Beckel JM, Birder LA, et al. Expression of nicotinic acetylcholine receptors in human bladder epithelial cells. Soc Neurosci Abstr 2001;27:2136
   Google Scholar
• Nandigama R, Ibañez-Tallon I, Lips KS, et al. Expression of nicotinic acetylcholine receptor subunit mRNA in mouse bladder afferent neurons. Neuroscience 2013;229:27-35
   PubMed Web of Science ®Google Scholar
• Masuda H, Hayashi Y, Chancellor MB, et al. Role of peripheral and central nicotinic receptors in the micturition reflex in rats. J Urol 2006;176:374-9
   PubMed Web of Science ®Google Scholar
• Farrerons C, Catena J, Fernandez-Serrat A, et al. Carbamates derived from arylalkylamines. PCT/ES01/00252, WO02/00652; 2002
   Google Scholar
• Viayna C, Alvarez D, Lopez R, et al. A randomised, placebo-controlled, dose rising study in healthy males volunteers to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of SVT-40776, a novel selective M3 antimuscarinic [abstract 270]. 34th Annual Meeting International Continence Society; 25-27 August 2004; Paris, France
   Google Scholar
• Salcedo C, Balsa D, Enrich A, et al. SVT-40776, a new selective M3 muscarinic antagonist: human receptor binding profile and bladder effects in the guinea-pig. Neurourol Urodyn 2003;22:382-4
   Google Scholar
• Balsa S, Salcedo C, Enrich A, et al. SVT-40776: a selective, competitive and reversible antagonist of the human recombinant muscarinic M3 receptor [abstract 260]. 34th Annual Meeting International Continence Society; 25-27 August 2004; Paris, France
   Google Scholar
• Ferńandez AG, Viayna C, Salcedo C, et al. Bladder selectivity of SVT-40776: a pharmacokinetic/pharmacodynamic (PK/PD) analysis based on preclinical and clinical studies [abstract 298]. 35th Annual Meeting International Continence Society; 28 August 2 September 2005; Montreal, Canada
   Google Scholar
• Salcedo C, Davalillo S, Cabellos J, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol 2009;156:807-17
   PubMed Web of Science ®Google Scholar
• Balsa D, Salcedo C, Enrich A, et al. Functional bladder selectivity of SVT-40776: a comparative study [abstract 284]. 35th Annual Meeting of the International Continence Society; 28 August 2 September 2005; Montreal, Canada
   Google Scholar
• Press release, REUTERS. 2010. Available from: http://www.reuters.com/article/2010/11/17/idUS215150+17-Nov-2010+BW20101117 [Last accessed 1 February 2014]
   Google Scholar
• ClinicalTrials.gov. Available from: www.clinicaltrials.gov/show/NCT01458197 [Last accessed 5 February 2014]
   Google Scholar
• Press release, SALVAT. 2013. Available from: http://www.salvatbiotech.com/en/noticias/salvat-and-kwang-dong-announced-positive-results-ofphase-iib-for-tarafenacin [Last accessed 10 February 2014]
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00409539 [Last accessed 10 February 2014]
   Google Scholar
• Paborji M, Duchin K, Flugel R. Phase I evaluation of THVD-201, a fixed dose combination of tolterodine and pilocarpine, to eliminate the dry mouth side effect of anti-muscarinic therapy for overactive bladder [abstract 882]. 26th Annual Congress European Association of Urology; 18-22 March 2011; Vienna, Austria
   Google Scholar
• Dmochowski R, Duchin K, Tremblay T, et al. Tolenix™ (THVD-201), a novel combination of muscarinic agonist (tolterodine) and muscarinic agonist (pilocarpine), is efficacious in OAB with less dry mouth compared to tolterodine alone [abstract 402]. 28th Annual Congress European Association of Urology; 15-19 March 2013; Milan, Italy
   Google Scholar
• Sweeney KR, Gastonguay MR, Benincosa L, et al. Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers. Drug Discov Ther 2010;4:44-53
   PubMedGoogle Scholar
• Flugel R, Paborji M, Tremblay T, et al. Dose escalation of muscarinic antagonist with THVD-201, a novel combination drug product containing tolterodine and pilocarpine (a muscarinic agonist and salivary stimulant) [abstract 293]. 43rd Annual Scientific Meeting of the International Continence Society. 26-30 August 2013; Barcelona, Spain
   Google Scholar
• Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001;19:319-23
   PubMed Web of Science ®Google Scholar
• Hughes KM, Lang JCT, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69
   PubMed Web of Science ®Google Scholar
• Waldeck K, Larsson B, Andersson K-E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997;157:1093-7
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000;95:718-21
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW. A short term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5
   PubMed Web of Science ®Google Scholar
• Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009;10:3103-11
   PubMed Web of Science ®Google Scholar
• Collas D, Malone-Lee JG. The pharmacokinetic properties of rectal oxybutynin – a possible alternative to intravescical administration. Neurourol Urodyn 1997;16:638-40
   Google Scholar
• Di Stasi SM, Giannantoni A, Vespasiani G, et al. Intravescical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol 2001;165:491-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT00196404 [Last accessed 14 February 2014]
   Google Scholar
• Gittelman M, Weiss H, Seidman L. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol 2013;191:1014-21
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT00685113 [Last accessed 14 February 2014]
   Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-7
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Press release, REUTERS. 2010. Available from: http://www.reuters.com/article/2010/11/17/idUS215150+17-Nov-2010+BW20101117 [Last accessed 16 February 2014]
   Google Scholar
• Rekik M, Rouget C, Palea S, et al. Effects of combining antimuscarinics and β3-adrenoceptor agonists on contractions induced by electrical fields stimulation of rat isolated urinary bladder strips [abstract 283]. 60th Annual Clinical Meeting of the American College of Obstetricians and Gynaecologist (ACOG). 5-9 May 2012; San Diego, California
   Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) – efficacy and safety results from a randomised phase 2 study (Simphony) [abstract 295]. 43rd Annual Scientific Meeting of the International Continence Society. 26-30 August 2013; Barcelona, Spain
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01340027 [Last accessed 18 February 2014]
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01908829 [Last accessed 18 February 2014]
   Google Scholar
• Stone CA, Torchiana ML, Navarro A, Beyer KH. Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine. J Pharmacol Exp Ther 1956;117:169-83
   PubMed Web of Science ®Google Scholar
• Ford RV, Madison JC, Moyer JH. Pharmacology of mecamylamine. Am J Med Sci 1956;232:129-43
   PubMed Web of Science ®Google Scholar
• Varanda WA, Aracava Y, Sherby SM, et al. The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol Pharmacol 1985;28:128-37
   PubMed Web of Science ®Google Scholar
• Shytle RD, Penny E, Silver AA, et al. Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens 2002a;16:453-7
   PubMed Web of Science ®Google Scholar
• Nickell JR, Grinevich VP, Siripurapu KB, et al. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacol Biochem Behav 2013;108:28-43
   PubMed Web of Science ®Google Scholar
• Press release. News Medical. Available from: http://www.news-medical.net/news/20140210/Targacept-completes-patient-recruitment-in-TC-5214-Phase-2b-study-for-treatment-of-overactive-bladder.aspx [Last accessed 20 February 2014]
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01868516 [Last accessed 20 February 2014]
   Google Scholar
• Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn 2007;26(6 Suppl):934-47
   PubMed Web of Science ®Google Scholar
• Andersson KE. Drugs and future candidates. Can Urol Assoc J 2011;5(5 Suppl 2):S131-3
   PubMedGoogle Scholar
• Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drug 2007;16:999-1007
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Cruz F. The medical treatment of overactive bladder, including current and future treatments. Expert Opin Pharmacother 2011;12:1401-55
   Google Scholar
• Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Grabiel Z, et al. The effects of antimuscarinic treatment in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. Systematic review and meta-analysis of randomized controlled trials with antimuscarinic drug for overactive bladder. Eur Urol 2008;54:740-63
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005;95:81-5
   PubMed Web of Science ®Google Scholar
• Sears CL, Lewis C, Noel K, et al. Overactive bladder medication adherence when medication is free to patients. J Urol 2010;183:1077-81
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rosenberg MT, Brenes FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009;104:960-7
   PubMed Web of Science ®Google Scholar
• Staskin D, Khullar V, Michel MC, et al. Effects of voluntary dose escalation in a placebo-controlled,flexible- dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 2011;30:1480-5
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30:1766-81
   PubMed Web of Science ®Google Scholar